These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18946749)

  • 1. Basal-like subtype and BRCA1 dysfunction in breast cancers.
    Miyoshi Y; Murase K; Oh K
    Int J Clin Oncol; 2008 Oct; 13(5):395-400. PubMed ID: 18946749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
    Rodríguez-Pinilla SM; Sarrió D; Honrado E; Moreno-Bueno G; Hardisson D; Calero F; Benítez J; Palacios J
    J Clin Pathol; 2007 Sep; 60(9):1006-12. PubMed ID: 17105822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction.
    Ohta T; Wu W; Koike A; Asakawa H; Koizumi H; Fukuda M
    Breast Cancer; 2009; 16(4):268-74. PubMed ID: 19459031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].
    Vincent-Salomon A; Macgrogan G; Charaffe-Jauffret E; Jacquemier J; Arnould L
    Bull Cancer; 2010 Mar; 97(3):357-63. PubMed ID: 20197250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
    Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
    Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
    Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
    J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
    PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors for anthracycline-based chemotherapy for human breast cancer.
    Miyoshi Y; Kurosumi M; Kurebayashi J; Matsuura N; Takahashi M; Tokunaga E; Egawa C; Masuda N; Kono S; Morimoto K; Kim SJ; Okishiro M; Yanagisawa T; Ueda S; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer; 2010 Apr; 17(2):103-9. PubMed ID: 19657712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
    Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
    Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
    Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J
    Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
    Santarosa M; Maestro R
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):131-42. PubMed ID: 22101651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options for triple-negative breast cancers with defective homologous recombination.
    Jaspers JE; Rottenberg S; Jonkers J
    Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
    Alli E; Ford JM
    DNA Repair (Amst); 2012 May; 11(5):522-4. PubMed ID: 22425348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
    Curigliano G; Goldhirsch A
    J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basal phenotype of BRCA1-related breast cancer: past, present and future.
    Tischkowitz MD; Foulkes WD
    Cell Cycle; 2006 May; 5(9):963-7. PubMed ID: 16687925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review].
    Clergue O; Jones N; Sévenet N; Quenel-Tueux N; Debled M
    Bull Cancer; 2015 Mar; 102(3):245-55. PubMed ID: 25758301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
    Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
    BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.